Onclive articles Copyright (c) 2014 Intellisphere, LLC. All rights reserved. http://www.onclive.com/articles Onclive articles Onclive articles en-us Tue, 30 Jun 2015 16:48:10 UTC 5 Onclive articles 144 47 http://www.onclive.com/articles http://www.onclive.com/media/image/35ab4bcc0544887940a968b55494cbb1.jpg <![CDATA[Celgene, Juno Ink $1 Billion Immunotherapy Deal]]>http://www.onclive.com/web-exclusives/celgene-juno-ink-1-billion-immunotherapy-dealOnclive articlesusTue, 30 Jun 2015 14:58:00 UTCOnclive<![CDATA[Krebs Cycle: A Role for Metabolic Enzymes in Acute Myeloid Leukemia]]>http://www.onclive.com/publications/Oncology-live/2015/July-2015/Krebs-Cycle-A-Role-for-Metabolic-Enzymes-in-Acute-Myeloid-LeukemiaOnclive articlesusMon, 29 Jun 2015 17:10:00 UTCOnclive<![CDATA[A Call for Tackling Smoking Cessation in Cancer Patients]]>http://www.onclive.com/publications/Oncology-live/2015/July-2015/A-Call-for-Tackling-Smoking-Cessation-in-Cancer-PatientsOnclive articlesusMon, 29 Jun 2015 13:00:00 UTCOnclive<![CDATA[A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial]]>http://www.onclive.com/publications/contemporary-radiation-oncology/2015/june-2015/A-Phase-III-Randomized-Trial-of-MRI-Mapped-Dose-Escalated-Salvage-Radiotherapy-Post-Prostatectomy-The-MAPS-TrialOnclive articlesusSun, 28 Jun 2015 16:00:00 UTCOnclive<![CDATA[ASCO Roundup: Nearly 30 Phase III Study Findings at a Glance]]>http://www.onclive.com/publications/Oncology-live/2015/July-2015/ASCO-Roundup-Nearly-30-Phase-III-Study-Findings-at-a-GlanceOnclive articlesusSat, 27 Jun 2015 16:00:00 UTCOnclive<![CDATA[Adding Brentuximab Vedotin to R-CHOP Induces 80% Response Rate in DLBCL]]>http://www.onclive.com/web-exclusives/Adding-Brentuximab-Vedotin-to-Frontline-R-CHOP-Results-in-80-Response-Rate-in-Advanced-DLBCLOnclive articlesusFri, 26 Jun 2015 21:04:00 UTCOnclive<![CDATA[Novel Combination Strategies Explored in Two Phase III NHL Studies]]>http://www.onclive.com/web-exclusives/Novel-Combination-Strategies-Explored-in-Two-Phase-III-NHL-StudiesOnclive articlesusFri, 26 Jun 2015 20:58:00 UTCOnclive<![CDATA[Soaring Prices for Oncolytics Prompt Payer Pushback]]>http://www.onclive.com/publications/oncology-business-news/2015/July-2015/Soaring-Prices-for-Oncolytics-Prompt-Payer-PushbackOnclive articlesusFri, 26 Jun 2015 15:56:00 UTCOnclive<![CDATA[Immunotherapy in Melanoma: What Does the Future Hold?]]>http://www.onclive.com/web-exclusives/Immunotherapy-in-Melanoma-What-Does-the-Future-HoldOnclive articlesusThu, 25 Jun 2015 20:32:00 UTCOnclive<![CDATA[Initial Phase III Data Positive for CPX-351 in High-Risk AML]]>http://www.onclive.com/web-exclusives/Initial-Phase-III-Data-Positive-for-CPX-351-in-High-Risk-AMLOnclive articlesusThu, 25 Jun 2015 17:45:00 UTCOnclive